A unique, multifaceted research strategy in immuno‑oncology1

True innovation takes time and an unwavering commitment to change the lives of patients and caregivers impacted by cancer. At NewLink Genetics we will stop at nothing to bring new immuno-oncology treatments to those who need them by relentlessly pursuing innovation and medical inspiration.

NewLink Genetics’ wide range of immuno-oncology portfolio candidates are poised to change the oncology landscape. Our immuno-oncology pipeline includes various clinical candidates designed to harness multiple components of the immune system to combat a wide range of cancers.

 
IDO-Pathway-New-Chart-Layout-04
View the data (clinical posters and presentations) http://investors.linkp.com/publications.cfm
IDO=indoleamine 2,3-dioxygenase; All agents are investigational—safety and efficacy not established.

 

References


1. National Institutes of Health. Clinicaltrials.gov. https://clinicaltrials.gov/ct2/results?term=algenpantucel-L&Search=Search and https://clinicaltrials.gov/ct2/results?term=indoximod&Search=Search. Accessed October 3, 2015.